Otros idiomas Pharmala Biotech Holdings Inc.

Acciones

Mercado cerrado - Canadian Securities Exchange Otros sitios de cotización 21:59:30 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
0,21 ^CAD	+2,44 %		-.--%	+50,00 %

05/04	PharmAla Biotech proporciona información actualizada sobre Australia	MT
27/03	Pharmala Biotech Holdings Inc. La Oficina de Patentes y Marcas de EE.UU. concede una autorización para la composición Ala-002	CI

PharmAla Biotech Advances Global MDMA Production and Research	24/04
PharmAla Closes Private Placement and Concurrent Debt Settlement	22/04
Pharmala Biotech Completes $750,000 Private Placement, Debt Settlement	19/04
PharmAla Closes Private Placement and Concurrent Debt Settlement	19/04
PharmAla Closes Private Placement and Concurrent Debt Settlement	19/04
Pharmala Biotech Holdings Inc. announced that it has received CAD 0.75 million in funding	19/04
PharmAla Announces Private Placement and Concurrent Debt Settlement	10/04
Pharmala Biotech Holdings Inc. announced that it expects to receive CAD 0.75 million in funding	10/04
Cortexa Commences Manufacturing GMP LaNeo MDMA In Australia	08/04
PharmAla Biotech Provides Australian Update	05/04
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia	05/04
US Patent and Trademark Office Grants Patent Allowance to Pharmala Biotech Holdings Inc. for ALA-002 Composition	27/03
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office	27/03
Pharmala Biotech Holdings Inc. Allowance Granted for Ala-002 Composition by US Patent and Trademark Office	27/03
PharmAla Biotech Signs Sale Agreement with Numinus Wellness	26/03
PharmAla Biotech Signs Sale Agreement with Numinus	26/03
PharmAla Biotech Signs Sale Agreement with Numinus	26/03
Pharmala Biotech Holdings Inc. Signs Sale Agreement with Numinus	26/03
PharmAla Says Patent Allowance Granted for P-1 Molecule by USPTO	20/03
Canadian Investment Regulatory Organization Trade Resumption - MDMA	20/03

No hay resultados para esta búsqueda